A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

  • End date
    Mar 31, 2023
  • participants needed
  • sponsor
Updated on 8 September 2021
duchenne muscular dystrophy
serum electrolyte


To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne muscular dystrophy (age 6 to <12 years).


This is a global, randomized, double-blind, trial of pamrevlumab or placebo in combination with systemic corticosteroids in subjects with Duchenne muscular dystrophy, aged 6 to <12 years (ambulatory subjects only). Approximately 70 subjects will be randomized at a 1:1 ratio to Arm A (pamrevlumab + systemic deflazacort or equivalent potency of corticosteroids administered orally) or Arm B (placebo+ systemic deflazacort or equivalent potency of corticosteroids administered orally), respectively.

Subjects must be fully informed of the potential benefits of approved products and make an informed decision when participating in a clinical trial in which they could be randomized to placebo.

Subjects will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab or placebo. Randomization will be stratified by exon 44 deletion.

The main study has three study periods:

  • Screening period: Up to 4 weeks
  • Treatment period: 52 weeks
  • Safety Follow-up period/final assessment: A visit 28 days (+/- 3 Days) and a final safety follow-up phone call 60 days (+ 3 Days) after the last dose

Each subject will receive pamrevlumab or placebo at 35 mg/kg every 2 weeks for up to 52 weeks. Subjects who complete 52 weeks of treatment may be eligible for an open-label extension (OLE), offering extended treatment with pamrevlumab.

Subjects who discontinue study treatment for any reason should be encouraged to return to the investigative site to complete final safety and efficacy assessments.

Condition Muscular Dystrophy, DUCHENNE MUSCULAR DYSTROPHY
Treatment Placebo, Pamrevlumab
Clinical Study IdentifierNCT04632940
Last Modified on8 September 2021


Yes No Not Sure

Inclusion Criteria

Age, and consent
Males at least 6 to <12 years of age at screening initiation
Written consent by legal guardian as per regional/ country and/or IRB/IEC requirements
DMD diagnosis
\. Medical history includes diagnosis of DMD and confirmed Duchenne mutation
using a validated genetic test
Pulmonary criteria
\. Average (of screening and day 0) percent predicted FVC above 45%
\. On a stable dose of systemic corticosteroids for a minimum of 6 months
with no substantial change in dosage for a minimum of 3 months (except for
adjustments for changes in body weight) prior to screening. Corticosteroid
dosage should be in compliance with the DMD Care Considerations Working Group
recommendations (e.g. prednisone or prednisolone 0.75 mg/kg per day or
deflazacort 0.9 mg/kg per day) or stable dose. A reasonable expectation is
that dosage and dosing regimen would not change significantly for the duration
of the study
Performance criteria
\. Able to complete 6MWD test with a distance of at least 270M but no more
than 450M on two occasions within 3 months prior to Randomization with 10%
variation between these two tests
\. Able to rise (TTSTAND) from floor in <10 seconds (without aids/orthoses)
at screening visit
\. Able to undergo MRI test for the lower extremities vastus lateralis
\. Received pneumococcal vaccine (PPSV23) (or any other pneumococcal polysaccharide vaccine as per national recommendations) and is receiving annual influenza vaccinations
Laboratory criteria
\. Adequate renal function: cystatin C 1.4 mg/L
\. Adequate hematology and electrolytes parameters
Platelets >100,000/mcL
Hemoglobin >12 g/dL
Absolute neutrophil count >1500 /L
Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P) levels are within a clinically accepted range
Adequate hepatic function
No history or evidence of liver disease
Gamma glutamyl transferase (GGT) 3x upper limit of normal (ULN)
Total bilirubin 1.5xULN

Exclusion Criteria

General Criteria
Concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function
Severe intellectual impairment (eg, severe autism, severe cognitive impairment, severe behavioral disturbances) preventing the ability to perform study assessments in the Investigator's judgment
Previous exposure to pamrevlumab
BMI 40 kg/m2 or weight >117 kg
History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
Exposure to any investigational drug (for DMD or not), in the 30 days prior to screening initiation or use of approved DMD therapies (e.g., eteplirsen, ataluren, golodirsen) within 5 half-lives of screening, whichever is longer with the exception of the systemic corticosteroids, including deflazacort
Pulmonary and Cardiac criteria
\. Requires 16 hours continuous ventilation
\. Poorly controlled asthma or underlying lung disease such as bronchitis
bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the
investigator might impact respiratory function
\. Hospitalization due to respiratory failure within the 8 weeks prior to
\. Severe uncontrolled heart failure (NYHA Classes III-IV), including any of
Need for intravenous diuretics or inotropic support within 8 weeks prior to screening
Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks prior to screening
Arrhythmia requiring anti-arrhythmic therapy
Any other evidence of clinically significant structural or functional heart abnormality
Clinical judgment
\. The Investigator judges that the subject will be unable to fully
participate in the study and complete it for any reason, including inability
to comply with study procedures and treatment, or any other relevant medical
surgical or psychiatric conditions
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note